Comparative treatment effectiveness of oral fingolimod and injectable disease modifying agents in multiple sclerosis

被引：0
|
作者：
Earla, Jagadeswara Rao [1 ]
Hutton, George Joseph [2 ]
Thornton, J. Douglas [1 ]
Chen, Hua [1 ]
Johnson, Michael L. [1 ]
Aparasu, Rajender R. [1 ]
机构：
[1] Univ Houston, Coll Pharm, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
3956
引用
收藏
页码：118 / 118
页数：1
相关论文
共 50 条
  • [1] Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis
    Earla, Jagadeswara R.
    Hutton, George J.
    Thornton, Douglas J.
    Chen, Hua
    Johnson, Michael L.
    Aparasu, Rajender R.
    PHARMACOTHERAPY, 2021, 41 (05): : 440 - 450
  • [2] COMPARATIVE ADHERENCE TRAJECTORIES OF ORAL FINGOLIMOD AND INJECTABLE DISEASE MODIFYING AGENTS IN MULTIPLE SCLEROSIS
    Earla, J. R.
    Hutton, G. J.
    Thornton, J. D.
    Chen, H.
    Johnson, M. L.
    Aparasu, R.
    VALUE IN HEALTH, 2020, 23 : S279 - S279
  • [3] Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis
    Earla, Jagadeswara R.
    Hutton, George J.
    Thornton, J. Douglas
    Chen, Hua
    Johnson, Michael L.
    Aparasu, Rajender R.
    PATIENT PREFERENCE AND ADHERENCE, 2020, 14 : 2187 - 2199
  • [4] Injectable disease modifying agents in multiple sclerosis: pattern of medication use and clinical effectiveness
    Jarvinen, Elina
    Holmberg, Markus
    Sumelahti, Marja-Liisa
    NEUROLOGY INTERNATIONAL, 2016, 8 (03) : 39 - 41
  • [5] Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis
    Earla, Jagadeswara Rao
    Hutton, George J.
    Thornton, J. Douglas
    Chen, Hua
    Johnson, Michael L.
    Aparasu, Rajender R.
    EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY, 2021, 2
  • [6] Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis
    E. Ann Yeh
    B. Weinstock-Guttman
    Advances in Therapy, 2011, 28 : 270 - 278
  • [7] Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis
    Earla, Jagadeswara Rao
    Li, Jieni
    Hutton, George J.
    Johnson, Michael L.
    Aparasu, Rajender R.
    PHARMACOTHERAPY, 2023, 43 (06): : 473 - 484
  • [8] Fingolimod: an Oral Disease-Modifying Therapy for Relapsing Multiple Sclerosis
    Yeh, E. Ann
    Weinstock-Guttman, B.
    ADVANCES IN THERAPY, 2011, 28 (04) : 270 - 278
  • [9] Cost-Effectiveness of Injectable Disease-Modifying Therapies in the Treatment of Multiple Sclerosis
    Quach, Jayson
    Dembek, Carole
    Szkurhan, Andrea
    Rashid, Nazia
    Blasco, M. R.
    NEUROLOGY, 2011, 76 (09) : A474 - A474
  • [10] PERSISTENCE TO ORAL AND INJECTABLE MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES
    Galaznik, A.
    Rusli, E.
    Lempernesse, B.
    Shilnikova, A.
    Ransom, J.
    Berger, M.
    VALUE IN HEALTH, 2019, 22 : S287 - S287
12345